MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2024 International Congress

    TM9SF2 Knockdown Decreases Pathological Alpha-synuclein Aggregation In Vivo

    C. Sortwell, R. Kumaran, F. Manfredsson, C. Kemp, M. Benskey, J. Patterson, A. Stoll, J. Howe, N. Kuhn, K. Luk, M. Cookson (Grand Rapids, USA)

    Objective: To determine whether knockdown of transmembrane 9 super family 2 (TM9SF2) decreases the formation of alpha-synuclein inclusions and toxicity to nigral neurons in the…
  • 2024 International Congress

    Consistent downregulation of rarely reported antioxidant genes viz., GGL, TR, TrX, HO-1, GR, GS, in the mid brain regions among mice and Drosophila exposed to Parkinsonian toxins: Scope as early diagnostic markers

    G. Chandran, R. D'Silva, A. Ashok (Mysuru, India)

    Objective: The study aimed at deciphering status of redox genes in mid-brain regions of 2 major in vivo study models: mice/Drosophila melanogaster exposed to Parkinson…
  • 2024 International Congress

    Immunoproteasome subunits as emerging contributors to neurodegeneration in Parkinson’s Disease

    HD. Nguyen, YE. Kim (Anyang-si, Gyeonggi-do, Republic of Korea)

    Objective: To gain comprehensive contribution of immunoproteasome in central nervous system of Parkinson's Disease Background: Recent investigations have elucidated that, in addition to the classical…
  • 2024 International Congress

    Melatonin Modulates NLRP3 Inflammasome Activation through TLR2 to Protect Against Parkinson’s Disease

    XY. Wang, JW. Li, HS. Liu, XN. Xiong (Wuhan, China)

    Objective: This study aims to investigate the impact of MLT on inflammation signaling pathway mediated by TLR2 in α-synuclein (α-syn) overexpressed BV2 cells and PD…
  • 2024 International Congress

    Investigating the pathogenesis of GBA1-associated Parkinson’s disease using GBA1 isogenic iPSC lines

    Y. Chen, C. Chen, C. Ma, J. Lichtenberg, E. Hertz, T. Jong, R. Sam, Y. Li, S. Vrisjen, P. Vangheluwe, C. Blauwendraat, E. Sidransky (Bethesda, USA)

    Objective: We aim to explore the pathogenesis of GBA1-associated synucleinopathies and discern the gain- vs. loss-of-function hypotheses by genetically engineering GBA1 in an iPSC line derived…
  • 2024 International Congress

    Exercise-induced angiogenesis and midbrain neuroprotection in a mouse model of experimental PD

    T. Rodriguez, R. Smeyne, M. Smeyne (Philadelphia, USA)

    Objective: The goal of this study is to characterize microvascular changes in the SNpc in response to a neuroprotective bout of exercise. Background: Parkinson’s disease…
  • 2024 International Congress

    Parkin regulates ER-mitochondria association through interaction with IP3R-Grp75-VDAC1

    NJ. Xue, Y. Liu, ZH. Lin, BR. Zhang, JL. Pu (Hangzhou, China)

    Objective: The objective of this study is to explore how Parkin modulates the interplay between mitochondria and the endoplasmic reticulum (ER), along with elucidating its…
  • 2024 International Congress

    The LRRK2 I1371V mutation alters membrane dynamics and inflammatory profile of astrocytes differentiated from LRRK2-I1371V PD Patient iPSCs

    R. Banerjee, V. Holla, N. Kamble, R. Yadav, P. Pal, I. Datta (Bengaluru, India)

    Objective: To evaluate the membrane dynamics and inflammatory profile of astrocytes differentiated from LRRK2-I1371V PD iPSCs in the presence and absence of extracellular α-Synuclein. Background:…
  • 2024 International Congress

    Pharmacokinetic-Pharmacodynamic Modeling of Amantadine Extended-Release Capsule Effects on Dyskinesia in Parkinson Disease

    Z. Wang, R. Gomeni, R. Pahwa, R. Hauser, A. Formella, M. Grall, H. Upadhyaya, J. Rubin (Rockville, USA)

    Objective: Evaluate pharmacokinetic/pharmacodynamic (PK/PD) relationships for the delayed- and extended-release (DR/ER) capsule formulation of amantadine [1] in the treatment of levodopa-related dyskinesia in Parkinson disease.…
  • 2024 International Congress

    The challenge to prevent Parkinson’s Disease with a new in vitro approach

    C. Dalla Verde, S. Gazzin, C. Tiribelli (Trieste, Italy)

    Objective: This research line aims to perform a compound screening on the prophylactic capacity of a high number of nutraceuticals and drugs to prevent dopaminergic…
  • « Previous Page
  • 1
  • …
  • 421
  • 422
  • 423
  • 424
  • 425
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley